Congrats to the Clear Cell Sarcoma Foundation on this poster #CTOS2024
Awesome, patient & patient-advocate driven work using digital connections to put together real-world datasets.

#CTOS2024 #sarcoma 3.6% second primary malignancy rate in kids treated for resectable EWS, majority hematologic. Pending multivariable analysis to delineate whether more chemo/which regimens have highest risk.

It was a dream come true getting to present the #TGCT registry data (n=497) demonstrating a high pt burden of TGCT. Education efforts among clinicians is needed to facilitate early diagnosis, effective treatment, better treatment algorithms to reduce the impact of TGCT on patient lives. #CTOS2024

Well, CTOS and San Diego are certainly nailing the views at this meeting. #ctos2024

Think this year’s mid-dinner fireworks on the USS Midway might beat last year’s flame shooting bagpipe corps in Dublin. #CTOS2024

Watch the experts ⬇️⬇️⬇️

ReQuote from 🙅🏻‍♀️: Watch William D. Tap, MD, Nicholas M. Bernthal, MD, FAOA & Emanuela Palmerini, MD, PhD discuss the latest #TGCT updates following #CTOS2024 by @peerview.bsky.social in collab with TGCT Support- to participate, visit: PeerView.com/TGCT24

Love this idea for a surgical wound complication grading system that includes delay to chemotherapy, from Dr. Qureshi
at OSU #CTOS2024 #OncSky:

Appreciated thoughtful discussion from Dr. Laetsch from CHOP on why palbo + iri/tem may have had ⬇️ EFS in R/R EWS, relevant to other CDKi studies too:
1. Antagonism with CDK4/6i? (Cell cycle arrest?)
2. Hematologic TRAE -> less exposure?
3. Statistical noise?
#CTOS2024 #OncSky #sarcoma

#CTOS2024: What don't we know yet about PEComa? Great talk on why we still need to study an ultra-rare disease after identifying a first-line treatment.

(QR code to join work group in second photo)in